Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.
Jaclyn CarberryMark C PetrieMatthew M Y LeeKatriona BrooksbankRoss T CampbellRichard GoodPardeep S JhundPeter KellmanNinian N LangKenneth MangionPatrick B MarkAlex McConnachieJohn J V McMurrayBarbara MeyerVanessa OrchardAadil ShaukatStuart WatkinsPaul WelshNaveed SattarColin BerryKieran F DochertyPublished in: ESC heart failure (2024)
EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.
Keyphrases
- left ventricular
- heart failure
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- acute myocardial infarction
- liver failure
- multiple sclerosis
- left atrial
- blood pressure
- aortic stenosis
- oxidative stress
- respiratory failure
- emergency department
- aortic dissection
- adverse drug
- extracorporeal membrane oxygenation